http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 29 Jun 2026 15:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vir+Biotechnology%2C+Inc.++++++++++++++++Filed+by%3A+Ramasastry+Saira/26705884.html si-local-file:///var/storage/secattach/20260629/26705884.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vir+Biotechnology%2C+Inc.++++++++++++++++Filed+by%3A+Ramasastry+Saira/26705884.html Mon, 29 Jun 2026 15:07:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vir+Biotechnology%2C+Inc.++++++++++++++++Filed+by%3A+Ramasastry+Saira/26705884.html si-local-file:///var/storage/secattach/20260629/26705884.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Vir+Biotechnology%2C+Inc.++++++++++++++++Filed+by%3A+Ramasastry+Saira/26705884.html Mon, 29 Jun 2026 15:07:00 -0400 O.30973479 VIR http://www.streetinsider.com/Analyst+PT+Change/Vir+Biotechnology+%28VIR%29+PT+Raised+to+%2427+at+Morgan+Stanley/26633016.html Morgan Stanley analyst Michael Ulz raised the price target on Vir Biotechnology (NASDAQ: VIR) to $27.00 (from $23.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Vir+Biotechnology+%28VIR%29+PT+Raised+to+%2427+at+Morgan+Stanley/26633016.html Thu, 11 Jun 2026 08:24:05 -0400 VIR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631123.html si-local-file:///var/storage/secattach/20260610/26631123.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631123.html Wed, 10 Jun 2026 18:21:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631123.html si-local-file:///var/storage/secattach/20260610/26631123.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631123.html Wed, 10 Jun 2026 18:21:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631122.html si-local-file:///var/storage/secattach/20260610/26631122.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631122.html Wed, 10 Jun 2026 18:20:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631122.html si-local-file:///var/storage/secattach/20260610/26631122.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09++Filed+by%3A+Coughlin+Timothy/26631122.html Wed, 10 Jun 2026 18:20:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09/26630265.html si-local-file:///var/storage/secattach/20260610/26630265.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09/26630265.html Wed, 10 Jun 2026 16:27:00 -0400 O.30973479 VIR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09/26630265.html si-local-file:///var/storage/secattach/20260610/26630265.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vir+Biotechnology%2C+Inc.+++For%3A+Jun+09/26630265.html Wed, 10 Jun 2026 16:27:00 -0400 O.30973479 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html <p>Vir Biotechnology, Inc. (NASDAQ: VIR) announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026.</p> <p>Coughlin previously served as chief financial officer of Neurocrine Biosciences, Inc., where he helped transition the company from clinical-stage to a commercial pharmaceutical company. Before Neurocrine, he held positions at Catholic Health Initiatives as vice president of financial services and at Ernst & Young LLP as senior manager in the health sciences practice.</p> <p>The new board member currently serves as chair of the board of directors of aTyr Pharma, Inc. and sits on the boards http://www.streetinsider.com/Board+Changes/Vir+Biotechnology+appoints+Timothy+Coughlin+to+board+of+directors/26629820.html Wed, 10 Jun 2026 16:05:33 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Appointment+of+Timothy+Coughlin+to+its+Board+of+Directors/26629792.html <p> SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. </p><p> “We are pleased to welcome Tim to Vir Biotechnology’s Board of Directors at a pivotal moment for the company,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “Tim brings a strong background of strategic discipline and operational insight that has helped organizations evolve into fully integrated enterprises. His extensive experience as chief financial officer and board member spanning discovery through commercialization will be http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Appointment+of+Timothy+Coughlin+to+its+Board+of+Directors/26629792.html Wed, 10 Jun 2026 16:05:00 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Appointment+of+Timothy+Coughlin+to+its+Board+of+Directors/26629792.html <p> SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. </p><p> “We are pleased to welcome Tim to Vir Biotechnology’s Board of Directors at a pivotal moment for the company,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “Tim brings a strong background of strategic discipline and operational insight that has helped organizations evolve into fully integrated enterprises. His extensive experience as chief financial officer and board member spanning discovery through commercialization will be http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Appointment+of+Timothy+Coughlin+to+its+Board+of+Directors/26629792.html Wed, 10 Jun 2026 16:05:00 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Appointment+of+Timothy+Coughlin+to+its+Board+of+Directors/26629792.html <p> SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. </p><p> “We are pleased to welcome Tim to Vir Biotechnology’s Board of Directors at a pivotal moment for the company,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “Tim brings a strong background of strategic discipline and operational insight that has helped organizations evolve into fully integrated enterprises. His extensive experience as chief financial officer and board member spanning discovery through commercialization will be http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Appointment+of+Timothy+Coughlin+to+its+Board+of+Directors/26629792.html Wed, 10 Jun 2026 16:05:00 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Appointment+of+Timothy+Coughlin+to+its+Board+of+Directors/26629792.html <p> SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. </p><p> “We are pleased to welcome Tim to Vir Biotechnology’s Board of Directors at a pivotal moment for the company,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “Tim brings a strong background of strategic discipline and operational insight that has helped organizations evolve into fully integrated enterprises. His extensive experience as chief financial officer and board member spanning discovery through commercialization will be http://www.streetinsider.com/Press+Releases/Vir+Biotechnology+Announces+Appointment+of+Timothy+Coughlin+to+its+Board+of+Directors/26629792.html Wed, 10 Jun 2026 16:05:00 -0400 A.00437200 A.14120169 A.23841700 A.23940260 A.50201976 O.00185003 O.11387289 O.20436042 O.29684461 O.30973479 O.48111428 VIR